Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Intensity Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
Oslo University Hospital
Xencor, Inc.
Bristol-Myers Squibb
Incyte Corporation
Lytix Biopharma AS
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Bristol-Myers Squibb